Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study.

To validate the performance of automated Prostate Cancer Molecular Imaging Standardized Evaluation (aPROMISE) in quantifying total prostate disease burden with 18F-DCFPyL PET/CT and to evaluate the interobserver and histopathologic concordance in the establishment of dominant and index tumor. Patients with a recent diagnosis of intermediate/high-risk prostate cancer underwent 18F-DCFPyL-PET/CT for staging purpose. In positive-18F-DCFPyL-PET/CT scans, automated prostate tumor segmentation was performed using aPROMISE software and compared to an in-house semiautomatic-manual guided segmentation procedure.

Head-to-Head Comparison of [F]F-choline and Imaging of Prostate-Specific Membrane Antigen, Using [F]DCFPyL PET/CT, in Patients with Biochemical Recurrence of Prostate Cancer.

Purpose: To analyse diagnostic and therapeutic impact of molecular imaging TNM (miTNM) stage obtained with [F]DCFPyL versus [F]F-choline in head-to-head comparison in biochemical recurrence (BCR) of prostate cancer (PCa).

Material And Methods: Patients with BCR of PCa after radical treatment with previous [F]F-choline-PET/CT (negative or oligometastatic disease) were recruited to [F]DCFPyL-PET/CT. Patients were classified according to: grade group, European Association of Urology classification, PSA, PSA doubling time (PSAdt) and PSA velocity (PSAvel).